Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucose-dependent insulinotropic polypeptide (GIP) has been implicated in lipid metabolism in animals. In humans, however, there is no clear evidence of GIP effecting lipid metabolism. The present experiments were performed in order to elucidate the effects of GIP on regional adipose tissue metabolism. RESEARCH DESIGN AND METHODS: Eight healthy subjects were studied on four different occasions. Abdominal subcutaneous adipose tissue metabolism was assessed by measuring arterio-venous concentration differences and regional adipose tissue blood flow during GIP (1.5 pmol/kg/min) or saline infused intravenously alone or in combination with a hyperinsulinemic-hyperglycemic (HI-HG) clamp. RESULTS: During GIP and HI-HG clamp, abdominal subcutaneous adipose tissue blood flow, hydrolysis of circulating triacylglycerol (TAG) (P = 0.009), and glucose uptake (P = 0.03) increased significantly while free fatty acid (FFA) output (P = 0.04) and FFA/glycerol release ratio (P = 0.02) decreased compared with saline and HI-HG clamp. CONCLUSIONS: In conclusion, GIP in combination with hyperinsulinemia and slight hyperglycemia increased adipose tissue blood flow, glucose uptake, and FFA re-esterification, thus resulting in increased TAG deposition in abdominal subcutaneous adipose tissue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GIP targets the white adipose tissue (Figure 1) improving its buffering capacity by promoting postprandial triglyceride storage and fatty acids re-esterification [196].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [196]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TAG accumulation occurs during hyperinsulinaemic hyperglycemic clamps as a result of these metabolic processes [114].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [114]
Experimental — accuracy not yet measuredIn the citing paper
“Additional research verified that GIP did not alter energy metabolism or appetite, nor did it alter TAG clearance in the absence of insulin when compared with saline infusion of lipid emulsions [114].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [114]
In the citing paper
“In healthy lean humans, when infused alone, GIP did not modify the local metabolism in AT but it has been able to enhance the hydrolysis of TAG induced by insulin, glucose uptake and blood flow, at the same time reducing FFA output.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Self-citationIntegrative physiology of human adipose tissue
Frayn, K. N., Karpe, F., Fielding, B. A., Macdonald, I. A., & Coppack, S. W. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802326 · Cited by 467 · cited 2×
“Based on these findings, we hypothesized that GIP per se plays a role in the regulation of adipose tissue re-esterification of FFA, a process that is of central importance in adipose tissue handling of fatty acids (7,8).”
BackgroundDeacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401 · cited 1×
“In addition, arterial blood was analyzed for GIP (12) From the (1)Department of Clinical Physiology/Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark; the (2)Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; and the (3)Department of Endocrinology, Hvidovre Hospital, Hvidovre, D…”
MethodSelf-citationDeacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237 · cited 1×
“In vitro studies have shown that GIP stimulates lipolysis (16,17).”
BackgroundRuge, T., Hodson, L., Cheeseman, J., Dennis, A. L., Fielding, B. A., Humphreys, S. M., Frayn, K. N., & Karpe, F. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2090 · Cited by 156 · cited 2×
“This suggests that FFA derived from LPL-mediated hydrolysis of the circulating TAG was directed into the adipose tissue probably to be esterified and stored, similar to what has been shown previously in subjects examined in the fed state (8).”
BackgroundResultEffect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.
Wasada, T., McCorkle, K., Harris, V, Kawai, K., Howard, B., & Unger, R. H. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110335 · Cited by 153 · cited 1×
“Several animal studies support the idea that glucose-dependent insulinotropic polypeptide (GIP) may play a direct role in lipid metabolism, which could be to ensure efficient deposition of dietary fat in body stores in times of plenty (1,2).”
BackgroundSamra, J. S., Simpson, E. J., Clark, M. L., Forster, C. D., Humphreys, S. M., Macdonald, I. A., & Frayn, K. N. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e834 · Cited by 102 · cited 1×
“(15) have demonstrated that when adipose tissue blood flow increased by infusion of adrenaline, TAG hydrolysis increased exactly in parallel with increased blood flow, implying that TAG hydrolysis is normally limited by substrate delivery, which is consistent with our present study.”
ResultBeck, B., & Max, J. (1983) · Regulatory Peptides · doi:10.1016/0167-0115(83)90276-8 · Cited by 91
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Asmar, M., Tangaa, W., Madsbad, S., Hare, K., Astrup, A., Flint, A., Bülow, J., & Holst, J. J. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00639.2009 · Cited by 83 · cited 1×
“We recently studied the effect of GIP on the removal rates of plasma triacylglycerol (TAG) and on free fatty acid (FFA) concentrations, which were increased after either a mixed meal or infusion of Intralipid and insulin (6).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Ekberg, 2001, Stimulation of blood flow by C-peptide in patients with type 1 diabetes, Diabetologia, 44, A323
Cited by
Items 101–185 of 185
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
Janssen, J. A. M. J. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189191 · Cited by 20
“GIP in combination with hyperinsulinemia and a slight hyperglycemia, increases glucose uptake and lipogenesis, inhibits lipolysis, and thereby stimulates deposition of triglycerides in subcutaneous fat tissue [98].”
Lyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 18
Gonzalez, J. T., Green, B. P., Campbell, M. D., Rumbold, P. L. S., & Stevenson, E. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.41 · Cited by 18
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Ohlsson, B., Darwiche, G., Roth, B., & Höglund, P. (2018) · Food & Nutrition Research · doi:10.29219/fnr.v62.1328 · Cited by 15
“Apart from facilitating glucose-stimulated insulin secretion, GIP also has a role in obesity development through increased hydrolysis of circulating triacylglycerides, with subsequent re-esterification of free fatty acids into triacylglycerides in adipocytes (7).”
BackgroundAdipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
“It also promotes fatty acid re-esterification [78 , 79].”
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Maagensen, H., Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., & Knop, F. K. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00767-2 · Cited by 16
“Furthermore, GIP increases adipose tissue blood flow and hereby increases triacylglycerol deposition to the subcutaneous adipocytes in healthy individuals [38–40].”
BackgroundHeimburger, S. M. N., Nielsen, C. N., Calanna, S., Holst, J. J., Vilsbøll, T., Knop, F. K., & Christensen, M. B. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14545 · Cited by 13
Self-citationRoell, W. C., Alsina‐Fernandez, J., Qu, H., Coşkun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L. S., Sloop, K. W., Steele, J. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102298 · Cited by 13
“Acute GIP infusions have demonstrated increased triglyceride deposition/storage in adipose tissue [23 — 25], suggesting that GIPR agonism could increase adiposity.”
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans
Krogh, L. S. L., Henriksen, K., Stensen, S., Skov‐Jeppesen, K., Bergmann, N. C., Størling, J., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., Gasbjerg, L. S., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac015 · Cited by 13
Self-citationPharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
Wang, T., Ma, X., Tang, T., Higuchi, K., Peng, D., Zhang, R., Chen, M., Yan, J. Y., Wang, S., Yan, D., et al. (2017) · Nutrition and Diabetes · doi:10.1038/nutd.2017.28 · Cited by 13
Irwin, N., Montgomery, I. A., & Flatt, P. R. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114511005228 · Cited by 13
“GIP also enhances fatty acid re-esterification in abdominal adipose tissue in humans, resulting in increased TAG deposition (8) .”
Rasmussen, R. S., Langberg, L. S., Østergaard, F., Nielsen, S. W., Vestergaard, M. B., Skov‐Jeppesen, K., Hartmann, B., Johannesen, H. H., Holst, J. J., Haddock, B., et al. (2025) · Diabetes · doi:10.2337/db25-0149 · Cited by 13
Self-citationTakahashi, H., Nakajima, A., Matsumoto, Y., Mori, H., Inoue, K., Yamanouchi, H., Tanaka, K., Tomiga, Y., Miyahara, M., Yada, T., et al. (2022) · Food & Nutrition Research · doi:10.29219/fnr.v66.7870 · Cited by 12
The Enteroendocrine System in Obesity
Miedzybrodzka, E. L., Reimann, F., & Gribble, F. M. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_582 · Cited by 12
Boer, G. A., Hunt, J. E., Gabe, M. B. N., Windeløv, J. A., Sparre‐Ulrich, A. H., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15894 · Cited by 13
“In vitro studies have shown that GIP increases fatty acid uptake in adipocytes (Kim et al., 2007; Yip et al., 1998) and in humans, where infusion of GIP during a high-insulin, high-glucose clamp increased triglyceride deposition in subcutaneous adipose tissue (Asmar et al., 2010).”
BackgroundSelf-citationVascular and metabolic effects of adrenaline in adipose tissue in type 2 diabetes
Tobin, L., Simonsen, L., Galbo, H., & Bülow, J. (2012) · Nutrition and Diabetes · doi:10.1038/nutd.2012.19 · Cited by 14
Self-citationRudovich, N. N., Nikiforova, V. J., Otto, B., Pivovarova‐Ramich, O., Gögebakan, Ö., Erban, A., Möhlig, M., Weickert, M. O., Spranger, J., Tschöp, M. H., et al. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00154.2011 · Cited by 12
“Our studies indirectly support recently published observations showing that GIP in conditions of clamped hyperglycemia enhances fatty acid reesterification with a resulting decrease in circulating fatty acids (3) and with comparable although milder effects under euglyE612 GIP, GHRELIN, AND PLASMA METABOLOME”
ResultRodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Gorini, F., & Tonacci, A. (2025) · Nutrients · doi:10.3390/nu17142350 · Cited by 11
“…combination with hyperinsulinemia, GIP increases subcutaneous abdominal adipose tissue blood flow (ATBF) and stimulates triacylglyceride deposition in adipose tissue in lean humans without inducing any significant changes in ATBF response in obese subjects with decreased glucose tolerance [69,70].”
Okuma, H. (2025) · Cureus · doi:10.7759/cureus.83712 · Cited by 19
“The activation of GIP receptors in subcutaneous white adipose tissue has been shown to improve insulin sensitivity through increased postprandial TG uptake [32,33].”
Barbosa-Yañez, R. L., Markova, M., Dambeck, U., Honsek, C., Machann, J., Schüler, R., Kabisch, S., & Pfeiffer, A. F. H. (2019) · Peptides · doi:10.1016/j.peptides.2019.170237 · Cited by 9
“flow in adipose tissue, glucose uptake and FFA re-esterification [16].”
BackgroundDavies, I., & Tan, T. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2203911 · Cited by 10
“nation with hyperinsulinemia, increases blood flow to and TAG deposition in abdominal subcutaneous adipose tissue in healthy male volunteers [25,26].”
BackgroundInteractions between the Gut, the Brain and Brown Adipose Tissue Function
van den Beukel, J. C., & Grefhorst, A. (2014) · Frontiers of hormone research · doi:10.1159/000358320 · Cited by 10
Lyons, S. A., Lea, M. B. S., Parikh, M., Guo, Z., Kagdi, S., Bisnauth, A. R., Pitino, J. R., Ziai, S., Mir, N., Tyrrell, A. D., et al. (2025) · EMBO Reports · doi:10.1038/s44319-025-00582-7 · Cited by 9
“For example, in humans, GIP has been shown to increase AT blood fl ow (Asmar et al, 2010).”
Hayes, W. J., Bruckner, J. V., & Doull, J. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374367-1.00059-8 · Cited by 8
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 9
“Studies in humans illustrate that endothelial GIPR activation increases adipose perfusion and enhances delivery of dietary fatty acids to adipose depots; improving postprandial lipid uptake and reducing the fraction of triglyceride-derived substrates that spill over into the circulation [84, 85].”
Ohlsson, B., Darwiche, G., Roth, B., & Höglund, P. (2016) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2016.1202214 · Cited by 8
Babenko, A. Y., Neymark, A. E., Anisimova, K. A., & Nikolaevna, E. N. N. G. E. (2014) · Obesity and metabolism · doi:10.14341/omet201443-11 · Cited by 7
The GIPR is Predominantly Localized to Non-Adipocyte Cell Types Within White Adipose Tissue
Campbell, J. E., Beaudry, J. L., Svendsen, B., Baggio, L. L., Gordon, A. N., Ussher, J. R., Wong, C. K., Gribble, F. M., D’Alessio, D. A., Reimann, F., et al. (2022) · doi:10.2337/figshare.19184462 · Cited by 6
A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues
Sicinski, K. M., Sürmeli, D., Du, J., Raman, V. S., Montanari, V., Lee, M., Harwood, B. N., Kopin, A. S., Beinborn, M., & Kumar, K. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00111 · Cited by 7
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
“…clamp conditions, mimicking the post-prandial state, GIP further increases WAT blood flow and amplifies insulin-induced TGs hydrolysis [65], an effect maintained even when endogenous insulin secretion is suppressed [66], suggesting partial insulin-independent actions.”
Takeda, Y., Fujita, Y., Yanagimachi, T., Maruyama, N., Bessho, R., Sakagami, H., Honjo, J., Yokoyama, H., & Haneda, M. (2020) · Physiological Reports · doi:10.14814/phy2.14469 · Cited by 4
“…has been reported to have various physiological effects such as suppression of bone resorption (Nissen et al., 2014), stimulation of fat deposition (Asmar et al., 2010), and amplification of glucagon secretion during hypoglycemia (Christensen et al., 2015; Christensen, Vedtofte, Holst,…”
BackgroundRole of endogenous incretins in the regulation of postprandial lipoprotein metabolism
Taskinen, M., Matikainen, N., Björnson, E., Söderlund, S., Ainola, M., Hakkarainen, A., Lundbom, N. M. I., Sihlbom, C., Thorsell, A., Andersson, L., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1187 · Cited by 4
Self-citationKrogh, L. S. L., Helsted, M. M., Englund, A., Bergmann, N. C., Skov‐Jeppesen, K., Nielsen, C. K., Hansen, C. P., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70186 · Cited by 4
“51 We did not observe any effect of GIP(3-30)NH 2 infusion on circulating triglycerides in totally pancreatectomized individuals.”
Self-citationGut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“In the postprandial period, GIP enhances lipoprotein lipase-mediated clearance of chylomicron-associated TGs [221–223] and increases adipose tissue storage by facilitating FA uptake directly via GIP-R [126,218,222,224] or indirectly by augmenting insulin-mediated FA incorporation [225,226].”
Regulation of blood flow in adipose tissue: involvement of the cholinergic system
Sotorník, R., Baillargeon, J., Gagnon‐Auger, M., Ménard, J., Brassard, P., & Ardilouze, J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00016.2015 · Cited by 4
Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis
Provenzani, A., Mancuso, B., Stitch, R., Tuzzolino, F., Giusti, M. A., & Mattina, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1735987 · Cited by 2
“…acutely suppresses bone resorption and promotes lipid storage through anabolic actions in adipocytes, a paradoxical effect which, in combination with GLP-1R agonism, appears to reprogram signaling in a manner that reduces adiposity rather than promoting it (Nissen et al., 2014; Asmar et al., 2010).”
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Self-citationGIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid
Nauck, M. A., Blüher, M., Meyhöfer, S. M., Heitmann, E., & Görgens, S. W. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-2436 · Cited by 3
“GIP fördert im wAT die Durchblutung und erhöht die Glukoseaufnahme, die Wiederver-esterung freier Fettsäuren und die Speicherung von Triglyzeriden, wodurch zirkulierende freie Fettsäuren reduziert werden [67].”
BackgroundBattillo, D. J., & Malin, S. K. (2023) · Metabolites · doi:10.3390/metabo13020137 · Cited by 2
Safety of native glucose-dependent insulinotropic polypeptide in humans
Helsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171214 · Cited by 3
Calderon, R. M., Golczak, M., Paik, J., & Blaner, W. S. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.08.030 · Cited by 2
Gradel, A. K. J., Kildegaard, J., Porsgaard, T., Lykkesfeldt, J., & Refsgaard, H. H. F. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13574 · Cited by 2
Knop, F. K., & Christensen, M. (2012) · Diabetes · doi:10.2337/db12-0219 · Cited by 2
Avogaro, A. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70184 · Cited by 2
“17 Overall, incretins and their analogues support vascular health by improving endothelial function, reducing inflammation and oxidative stress, limiting plaque progression, enhancing endothelial repair and promoting NO-mediated vasodilation across multiple vascular beds.”
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.01.001 · Cited by 1
Song, S., Hyeon, M., Kim, S., Kang, Y., Hahm, S., Park, E. B., Shin, B. S., & Shin, S. (2026) · Journal of Analytical Science & Technology · doi:10.1186/s40543-026-00540-5 · Cited by 1
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
Takiyama, T., Kitsunai, H., Maruyama, F., Kitao, N., Wakabayashi, Y., Ito, M., Kurihara, H., Yamamoto, K., Takeuchi, J., Nanbu, T., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109391 · Cited by 1
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis
Tavaglione, F., & Loomba, R. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103023 · Cited by 1
“43–46 Importantly, beyond facilitating acute dietary triglyceride clearance, GIP may promote long-term tri-glyceride storage by supporting healthy expansion of white adipose tissue, including stimulation of pre-adipocyte differentiation ( de novo adipogenesis) and increasing adipocyte number rather…”
Smarkusz-Zarzecka, J., Radziszewska, M., Gofron, K. K., & Ostrowska, L. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10098-7 · Cited by 1
Fisiologia Pacreática: Pâncreas Endócrino
Montenegro, R. M., Chaves, M. M., & Fernandes, V. O. (2016) · doi:10.5151/9788580391893-20 · Cited by 9
Sotorník, R., Brassard, P., Ménard, J., Gagnon‐Auger, M., Baillargeon, J., & Ardilouze, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16589 · Cited by 1
“15 Likewise, GLP-1 has been shown to increase ATBF during systemic infusion.”
Next Step in Incretin-Based Therapy: From Single to Dual Agonism
Pramanik, S., & Ray, S. (2022) · EMJ Diabetes · doi:10.33590/emjdiabet/22-00140 · Cited by 2
“12 The effect of GIP on the gastrointestinal (GI) tract is incompletely understood; while GLP-1 slows gastric emptying, 13 this effect is not confirmed for GIP.”
BackgroundAdiponectin, Diabetes, and the Cardiovascular System
Gasbarrino, K., Boutari, C., Filippaios, A., Gianopoulos, I., Daskalopoulou, S. S., & Mantzoros, C. S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_8 · Cited by 1
Lempesis, I. G. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231019ll · Cited by 1
Merchant, C. E. (2011) · cIRcle (University of British Columbia) · doi:10.14288/1.0105089
Modulating Glycaemia with Cereal Products
Priebe, M. G., Eelderink, C., & Vonk, R. J. (2021) · Wiley eBooks · doi:10.1002/9781118939420.ch14
Ormoni gastrointestinali e terapia del diabete: dalla fisiologia alle nuove opportunità terapeutiche
Fadini, G. P. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01260-3 · Cited by 2
Sachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2912233/v1
Molecular endocrine pharmacology and therapeutics
Olaniyan, O. T., Adetunji, C. O., Okotie, G. E., & Ohanenye, C. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16013-4.00024-5
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2024) · Figshare · doi:10.6084/m9.figshare.26633796
Sachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611103
Sachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611100
Sachs, S., Goetz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2024) · Figshare · doi:10.6084/m9.figshare.26611097
Batırel, S., Cetinkaya, B., Sahin, A., Alakbarova, N., Guctekin, T., Özben, B., & Tigen, K. (2026) · Biomedicines · doi:10.3390/biomedicines14020260
“On the other hand, GIP’s lack of correlation with fasting lipids may be due to its predominant role in postprandial lipid handling, especially under insulin-sufficient conditions [33].”
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.12.005 · Cited by 1
Asmar, M., Bülow, J., Holst, J. J., & Asmar, A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag084
Self-citationBrayner, B., Mason, S. A., Karimi, E., Keske, M. A., Roberts‐Thomson, K. M., Parker, L., Betik, A. C., Thomas, H. J., Way, K. L., Livingstone, K. M., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00028.2026
Incretin-based therapies: Effects on plasma lipids and potential mechanisms
Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057
Gut Hormone Changes After Bariatric Surgery
Turner, B., & Kindel, T. L. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_7
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Rasmussen, R. S., Nielsen, S. W., Alstrup, L., Larsson, T. S. W., Hansen, J. K., Pedersen, R. P., Vestergaard, M. B., Haddock, B., Johannesen, H. H., Larsson, H. B. W., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06788-1 · Cited by 1
“Among other functions, GIP infusion, in combination with insulin, markedly increases (fivefold) adipose tissue blood flow (ATBF) and enhances triacylglycerol storage [9, 10] via local capillary recruitment [11].”
Self-citationResearch Progress of Tirzepatide in Metabolic Diseases
孙, 豪. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1672603
Lipid sensing and brain hormone receptors in food intake and glucose regulation
Garrido, A. N., Lyons, S. A., MOSLEMIAN, D., Beaudry, J. L., & Lam, T. K. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01278-1
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“Additionally, GIP may en-https hance the lipid-buffering capacity of white adipose tissue, thereby reducing ectopic fat accumulation in other tissues [186].”
Adipose tissue-on-Chip platforms for disease modelling, drug discovery and pharmacokinetic modelling
Castañé, H., Spangenberger, C., de Souza, I. R., Kristoforus, T., Lazarevski, L., Yim, J., Cipriano, M., Hjuler, S. T., Özkan, A., Petrie, T. A., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115971
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Güneşli, I., Aksun, M. S., & Yıldız, B. O. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03047-3
Metadata
- Authors
- Asmar, M., Simonsen, L., Madsbad, S., Stallknecht, B., Holst, J. J., & Bülow, J.
- Affiliations
- University of Copenhagen (DK)
- Bispebjerg Hospital (DK)
- Hvidovre Hospital (DK)
- Corresponding author
- Bülow, Jens
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-06-14
- Volume
- 59
- Issue
- 9
- Pages
- 2160-2163
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2927937
- OpenAlex
- W2122333141
- Cited by
- 184
- References
- 19
- Citations by year
- 2026: 25 · 2025: 17 · 2024: 14 · 2023: 14 · 2022: 15 · 2021: 9 · 2020: 8 · 2019: 18 · 2018: 9 · 2017: 6 · 2016: 9 · 2015: 5 · 2014: 6 · 2013: 9 · 2012: 8
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Keywords
- glucose-dependent insulinotropic polypeptide, fatty acid re-esterification, subcutaneous abdominal fat, adipose tissue blood flow, lipolysis, free fatty acid release, glucose uptake, lipid metabolism
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Fatty Acids, Gastric Inhibitory Polypeptide, Glycerol, Humans, Hyperglycemia, Hyperinsulinism, Male, Thinness, Triglycerides, Glucose Clamp Technique, Subcutaneous Fat, Abdominal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.